It has been recently reported that in a small number of patients with recurrent or refractory AML, treatment with mutant IDH1 or mutant IDH2 inhibitors may lead to clinical differentiation syndrome, which is characterized by leukocytosis and exuberant neutrophil recovery. This evidence concerns the gene IDH1 and acute myeloid leukemia.